Drug for alcohol de addiction

Reading File

Finding Sources

Searching PubMed

"alcohol use disorder" AND pharmacotherapy

Reading File

Here is a thorough, textbook-grounded overview of drugs used for alcohol de-addiction (alcohol use disorder, AUD):

Drugs for Alcohol De-Addiction (Alcohol Use Disorder)

Three medications are FDA-approved in the United States for relapse prevention in AUD. A fourth (disulfiram) is approved for aversion therapy. All work best when combined with behavioral/psychological support.

1. Naltrexone (First-line, SOR: A)

Forms: Oral 50 mg/day OR long-acting injectable 380 mg IM every 4 weeks (Vivitrol)

Mechanism: Opioid receptor antagonist (no agonist activity). Blocks mu-opioid receptors, reducing activity in the dopaminergic ventral tegmental reward pathway - blunts the pleasurable/euphoric effects of alcohol and decreases craving.

Efficacy: Randomized controlled trials consistently show fewer drinking days, fewer relapses, and lower craving vs. placebo. The injectable form may be especially useful in severe AUD or where compliance is a concern.

Side effects:

Nausea (~10%, self-limited)
Injection site reactions (injectable form)
Dose-related hepatotoxicity at high doses (300 mg/day) - NOT at standard doses
Mild LFT abnormalities are not a contraindication, but monitoring is recommended

Contraindications: Acute hepatitis, liver failure, concurrent opioid use. Ensure opioid abstinence for at least 7-10 days before starting (risk of severe opioid withdrawal).

2. Acamprosate (First-line, SOR: A)

Dose: 666 mg twice daily (or 333 mg three times daily if CrCl 30-50 mL/min); do not use if CrCl < 30 mL/min

Mechanism: Amino acid derivative - inhibits NMDA receptors and enhances GABA transmission, reducing the neuronal hyperexcitability (protracted withdrawal symptoms) that drives craving and relapse.

Efficacy: Effective for reducing return to alcohol use, particularly in patients who have already achieved abstinence. Works best for maintaining abstinence rather than reducing heavy drinking. One major US multicenter trial (COMBINE study) showed no benefit over placebo, but multiple European trials support efficacy.

Side effects: Minimal - mainly GI (diarrhea). Safe in liver disease (renally excreted, unlike naltrexone).

Combination: Naltrexone + acamprosate together may be more effective than either alone in some patients, though not all studies agree.

3. Disulfiram (SOR: B)

Dose: 250 mg/day (500 mg/day more effective but more side effects)

Mechanism: Irreversibly inhibits aldehyde dehydrogenase (ALDH) - the enzyme that metabolizes acetaldehyde (the toxic byproduct of alcohol metabolism). When alcohol is consumed, acetaldehyde accumulates rapidly, producing the disulfiram-ethanol reaction:

Flushing, nausea, vomiting, diaphoresis, tachycardia, hypotension

Efficacy: Primarily an aversion/deterrence strategy. Benefits most highly motivated, supervised patients. Best given under supervision (e.g., by a spouse), especially during high-risk periods.

Side effects and risks:

Can cause temporary depressive or psychotic symptoms
Peripheral neuropathy
Hepatotoxicity
The alcohol reaction itself can be dangerous in patients with heart disease, stroke, diabetes, or hypertension

Caution: Disulfiram also inhibits monoamine metabolism, so the reaction has both biochemical and central monoaminergic components.

4. Other Agents Under Investigation

These lack sufficient evidence for routine use but are being studied:

Drug	Proposed Mechanism
Nalmefene	Opioid antagonist (similar to naltrexone, approved in Europe)
Baclofen	GABA-B agonist; reduces craving
Topiramate	Anticonvulsant; reduces glutamate, enhances GABA
Gabapentin	GABA-A modulator; one RCT (1200 mg/day) showed benefit but not replicated
Ondansetron	5-HT3 antagonist; may help early-onset AUD
Varenicline	Nicotinic receptor agonist
Prazosin	Alpha-1 adrenergic agonist (with naltrexone)
GLP-1 agonists (e.g., semaglutide)	Emerging; may reduce reward-driven alcohol consumption
Psilocybin/Ketamine	Adjuncts to talk therapy; very early evidence

Emerging evidence (2024-2025): Two recent systematic reviews (PMIDs 39288591, 39969054) suggest GLP-1 receptor agonists (like semaglutide) may reduce alcohol-related behaviors and could represent a future therapeutic strategy for AUD - though evidence is still preliminary.

Summary Table

Drug	Mechanism	Main Use	Evidence Level
Naltrexone (oral/injectable)	Opioid antagonist	Reduce craving & relapse	SOR: A
Acamprosate	NMDA antagonist / GABA enhancer	Maintain abstinence	SOR: A
Disulfiram	ALDH inhibitor (aversion)	Deterrence in motivated patients	SOR: B
Nalmefene	Opioid antagonist	Reduce heavy drinking (EU-approved)	Moderate

Key Clinical Pearls

All three FDA-approved drugs (naltrexone, acamprosate, disulfiram) are adjuncts - they work best alongside cognitive-behavioral therapy (CBT), motivational interviewing, or AA.
Naltrexone is first-line for reducing heavy drinking and craving; the injectable form improves adherence.
Acamprosate is preferred in patients with liver disease (renally cleared) who have already achieved abstinence.
Disulfiram requires high motivation and ideally supervision; its risks outweigh benefits in most patients without these conditions.
Combination therapy (naltrexone + acamprosate) is an option when monotherapy is inadequate.

Sources: Goldman-Cecil Medicine; Harrison's Principles of Internal Medicine 22E; Tintinalli's Emergency Medicine; Textbook of Family Medicine 9e

This is a shared conversation. Sign in to Orris to start your own chat.